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Mutations of the voltage-gated sodium channel SCN8A have been identified in approx-
imately 1% of nearly 1,500 children with early-infantile epileptic encephalopathies (EIEE)
who have been tested by DNA sequencing. EIEE caused by mutation of SCN8A is desig-
nated EIEE13 (OMIM #614558). Affected children have seizure onset before 18months of
age as well as developmental and cognitive disabilities, movement disorders, and a high
incidence of sudden death (SUDEP). EIEE13 is caused by de novo missense mutations
of evolutionarily conserved residues in the Nav1.6 channel protein. One-third of the
mutations are recurrent, and many occur at CpG dinucleotides. In this review, we discuss
the effect of pathogenic mutations on the structure of the channel protein, the rate of
recurrent mutation, and changes in channel function underlying this devastating disorder.
Keywords: sodium channel, epilepsy, seizures, SUDEP, CpG, Dravet syndrome, mutation
Introduction
Neuronal voltage-gated sodium channels contain one large, pore-forming α subunit and two smaller
β subunits (1). They regulate cellular excitability by controlling the flowof sodium ions across the cell
membrane. The sodium channel α subunit genes SCN1A, SCN2A, and SCN8A are broadly expressed
in brain neurons, where they play a critical role in the regulation of neuronal excitability. Mutations
in each of these closely related genes can result in early-infantile epileptic encephalopathy (EIEE),
characterized by early-onset seizures that are refractory to treatment and accompanied by cognitive
and behavioral disabilities (2, 3). Mutations of SCN1A are responsible for EIEE6 (Dravet syndrome).
SCN2Amutations have been identified in EIEE11 (Ohtahara syndrome). Since 2012, more than 60
mutations of SCN8A have been identified in EIEE13 (OMIM #614558). In this article, we review the
emergence of SCN8A as an important cause of EIEE.
SCN8A encodes the voltage-gated sodium channel Nav1.6, the major sodium channel at nodes of
Ranvier (4) and at the axon initial segment (AIS) of excitatory and inhibitory neurons (5–7). At the
AIS, Nav1.6 regulates the initiation of action potentials (8), and at nodes of Ranvier it contributes to
nerve conduction velocity (9). The effects of loss of Nav1.6 have been studied in spontaneous mouse
mutants. Partial or complete loss of Nav1.6 in mice causes reduced neuronal excitability as well as
tremor, ataxia, and dystonia. Null mice develop hindlimb paralysis and death by 3weeks of age (3).
Heterozygous carriers of loss-of-function mutations in the mouse exhibit only mild abnormalities
including disrupted sleep architecture and elevated anxiety (10, 11). On some strain backgrounds,
heterozygous null mice exhibit spike–wave discharges, the hallmark of absence (non-convulsive)
epilepsy, without spontaneous convulsive seizures (12).
Discovery of Patient Mutations in SCN8A
The role of SCN8A in human disease was first examined by a candidate gene approach in families
segregating inherited movement disorders that resembled the defects in mutant mice. One family
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with a mutation of SCN8A was identified by this approach. The
proband had ataxia and intellectual disability and was found to be
heterozygous for a protein truncation mutation of SCN8A (13).
Three additional heterozygous family members had intellectual
disabilities without ataxia. It is important to note that none of
the heterozygous null individuals in this family had a history
of seizures, indicating that simple loss of SCN8A function is
not epileptogenic. A screen of 80 patients with familial essential
tremor failed to detect SCN8A variants (14). Analysis of families
with inherited ataxia was also negative (Meisler, unpublished
observations).
The recent introduction of exome sequencing in patients with
early-onset epileptic encephalopathy resulted in identification of
de novo mutation of SCN8A as an important cause of this non-
familial disorder. The first de novomutationwas found in a patient
with seizure onset at 6months of age (15). More than 60 de novo
mutations of SCN8A have since been identified by exome and
genome sequencing and, more recently, by inclusion of SCN8A
in commercial epilepsy gene sequencing panels (16–28).
Four studies utilized targeted sequencing strategies to identify
pathogenic variants in large cohorts of epileptic encephalopa-
thy patients. The proportion of EIEE cases with mutations in
SCN8A was 3/500 (17), 2/264 (18), 7/683 (25), and 1/110 (26).
Thus, mutations in SCN8A account for close to 1% of epileptic
encephalopathy.
Shared Clinical Features of EIEE13 Patients
Most patients with EIEE13 have seizure onset between birth
and 12months of age, with a median age of 4months. Sev-
eral patients exhibited seizures within a week or two of birth.
Generalized tonic and tonic–clonic seizures are present in most
patients. Atonic, myoclonic, and focal and absence seizures are
not uncommon. Febrile seizures are rare in EIEE13, providing a
useful distinction between EIEE13 and Dravet syndrome. Prior
to seizure onset, development is normal in approximately half
of patients. After seizure onset, developmental regression often
results in mild to severe intellectual disability. A distinguish-
ing feature of EIEE13 is the movement disorders, which range
from mild ataxia to choreoathetosis and, in several patients,
quadriplegia. Hypotonia and hypertonia are frequent, some-
times in the same patient. SUDEP has been reported in 5/40
patients.
EEG at or near the time of seizure onset is normal in approx-
imately 50% of cases. In the following months, most individuals
develop EEG abnormalities including focal or multi-focal sharp
waves or spikes, moderate to severe background slowing, and
spike–wave complexes. Hypsarrhythmia is rare.
MRI scans usually appear normal at onset of EIEE13. After
seizure onset, the MRI remains normal in approximately 50% of
patients. Themost commonMRI abnormality ismild diffuse atro-
phy or mild to moderate cerebral atrophy. Cerebellar atrophy and
thinning of the corpus callosumhas also been reported. The extent
of cerebral and cerebellar atrophy appears to be correlated with
severity of the movement disorder. Under-developed cortex and
defective myelination has been seen in a few cases. Microcephaly
is rare.
Drug Responses in Patients with EIEE13
Seizures in EIEE13 patients are typically refractory to treat-
ment, but up to 1/3 of patients have enjoyed seizure-free peri-
ods. Approximately, 40% of patients for whom we have detailed
clinical histories have responded favorably to anticonvulsants
that directly modulate sodium channel activity (“sodium chan-
nel blockers”) including valproic acid, phenytoin, carbamazepine,
oxcarbazepine, lamotrigine, and topiramate (Table 1). Monother-
apy with sodium channel blockers has been effective for some
patients. Sodium channel blockers have been effective in patients
with either gain-of-function or apparent loss-of-function muta-
tions. Carbamazepine and its derivative oxcarbazepine have been
useful in the largest number of patients. Patients carrying the
identical SCN8A mutation can differ in their drug responses,
indicating a significant role for modifier genes and/or stochastic
developmental processes (Tables 1 and 2).
The limited clinical evidence suggests that sodium channel
blockers may be the best first line treatments for patients with
SCN8A mutations, rather than modulators of GABA signaling
or other synaptic function. By contrast, sodium channel blockers
usually exacerbate seizures in patients with Dravet syndrome,
which is caused by a deficiency of SCN1A activity. EIEE13,
which is due to overactivity of SCN8A, has not been reported
to be exacerbated by sodium channel blockers. Seizure exac-
erbation in EIEE13 patients has been observed with adminis-
tration of levetiracetam. The ketogenic diet is reported to be
effective for as many as 1/3 of patients with Dravet Syndrome.
The response of patients with EIEE13 is not yet known. Early
diagnostic DNA sequencing to distinguish between EIEE13 and
Dravet Syndrome is thus very important for the selection of
treatment.
Recurrent Mutations of SCN8A
The known mutations of SCN8A in EIEE13 are missense muta-
tions that arose de novo in the patient or, in two cases, were inher-
ited from a mosaic parent. All of the missense mutations result
in substitution of an evolutionarily conserved amino acid residue.
The locations of these mutations are shown in Figure 1. One-
third of the mutations have reoccurred in two or more unrelated
individuals (Figure 1, open circles). The molecular alterations
in the recurrent mutations are indicated in Table 3. There have
been five occurrences of themissensemutation p.Arg1617Gln and
nine mutations of arginine residue 1872, four with substitution
of glutamine, three with substitution of tryptophan, and two with
substitution of leucine.
One-third of the recurrent mutations are located at CpG din-
ucleotide residues, e.g., in arginine codons 1872 (CGG) and
1617 (CGA). CpG dinucleotides are mutation hotspots that can
undergo enzymatic methylation of cytosine followed by spon-
taneous deamination of the methylated C to form thymine
(Figure 2). Both of these arginine codons contain CpG sequences
on coding and non-coding strands, and CpG deamination at
these sites can account for most of the observed amino acid
substitutions (Figure 2).
Clinical information is available for five patients with the
p.Arg1617Gln mutation. Remarkably, these patients differ in
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TABLE 1 | Reported drug response in epileptic encephalopathy due to SCN8A mutations.
Amino acid
substitution
Channel
domain
Effect on
function
Effective treatment Seizure response Reference
p.Val216Asp DIS3-4 VPA Seizure control (23)
p.Leu407Phe DIS6 CBZ 75% reduction (53)
p.Phe846Ser DIIS4 PHT, LTG, PB KD, VNS Temporarily effective (53)
p.Ala890Thr DIIS5 VPA Seizure control (25, 53)
VPA, OXC
p.Asn984Lys Near DIIS6 GOF PHT, ZNS, PB LEV, CLB Seizure control (24)
p.Ile1327Val DIIIS4-5 High PHT Temporarily effective (27)
p.Gly1451Ser DIIIS6 LOF CBZ Seizure control (24)
p.Asn1466Lys Inactivation gate PHT, TPM, GBP, ACTH, MDL, LD Temporarily effective (23)
p.Asn1466Thr Inactivation gate TPM, LEV Seizure control (23)
p.Val1592Leu DIVS3 OXC Seizure control (25)
p.Ser1596Cys DIVS3 OXC, LTG, PB, LEV 75% reduction (53)
p.Ile1605Arg DIVS3 CBZ Seizure control (25)
p.Arg1617Gln DIVS4 CBZ Temp. effective (23, 53)
OXC Seizure control
p.Ala1650Thr DIVS4-5 CBZ, TPM Seizure control (23)
p.Asn1768Asp DIVS6 GOF VPA, LTG, CLB Temporarily effective (15)
p.Arg1872Trp C-term TPM, LCM, LEV, VGB, KD Febrile breakthrough (23)
ACTH, adrenocorticotropic hormone; CBZ, carbamazepine; CLB, clobazam; GBP, gabapentin; KD, ketogenic diet; LCM, lacosamide; LD, lidocaine; LEV, levetiracetam; LTG, lamotrigine;
MDL, midazolam; OXC, oxcarbazepine; PB, phenobarbital; PHT, phenytoin; TPM, topiramate; VGB, vigabatrin; VNS, vagal nerve stimulator; VPA, valproic acid; ZNS, zonisamide. Drugs
classified as sodium channel blockers are indicated in bold.
TABLE 2 | Phenotypic variability in patients with the p.Arg1617Gln mutation in SCN8A.
Patient Age of
onset
Seizure type Developmental progression EEG Drug
response
Reference
1 3months Febrile seizures, tonic–clonic Sat, crawled 24 months Normal at 3months CBZ temp.
effective
(23)
2 5.5months Generalized tonic–clonic, tonic,
clonic, myoclonic, atypical absence
Hypotonia, wheelchair-bound, no
speech, SUDEP at 3 years
Bilateral delta slowing and left
temporal spikes and/or slow waves
Refractory (25)
3 6months Generalized tonic Head control 7months., sat
12months
Normal at 11months, spike and
spike–wave complexes in left
rolandic at 3 years
OXC
effective
(53)
4 7months Generalized tonic–clonic Spasticity, sat 8months, walked
17months, speech 24months
Not described No details (16)
5 12months Generalized tonic–clonic Not described Suggested anterior midline-frontal
onset
Refractory (21)
many respects, including age of seizure onset, seizure type, severity
of co-morbidities, and drug response (Table 2). These observa-
tions emphasize the important role of genetic background, includ-
ing variation in other ion channel genes, on the clinical outcome
for any individual patient.
Recurrent mutations of SCN1A have also been observed
in Dravet syndrome. Recurrent mutations account for 25% of
pathogenic mutations, and 1/3 of recurrent mutations are located
at CpG dinucleotides (29). Recurrent deletions of short direct
repeats that are susceptible to slipped-strand mispairing account
for generation of some null alleles of SCN1A.
Sodium channels are among the most highly conserved pro-
teins in the mammalian genome. SCN8A ranks among the 2%
of human proteins that are least tolerant of variation [see dataset
S2 in Ref. (30)]. The pathogenic missense mutations of SCN8A
identify a subset of residues whose substitution results in elevated
channel activity.
Location and Functional Consequences of
SCN8A Mutations
Sodium channel α subunits contain four homologous domains
(DI-DIV), each with six highly conserved transmembrane
segments designated S1–S6 (Figure 1). Less-conserved
cytoplasmic loops separate domains DI and DII, and domains
DII and DIII. Domains III and IV are separated by a short, highly
conserved inactivation gate (Figure 1). The proximal 2/3 of the
C-terminus (residues 1767–1912) harbors several binding sites
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FIGURE 1 | Positions of missense mutations of SCN8A in epileptic
encephalopathy. The four homologous domains of Nav1.6 (DI to DIV)
each contain six transmembrane segments (S1 to S6). The large
inter-domain cytoplasmic loops 1 and 2 are evolutionarily less
well-conserved than the transmembrane and linker domains. Loop 3
functions as the inactivation gate and is very highly conserved. Closed
symbols, EIEE13 mutations in a single patient; open symbols, recurrent
mutations.
TABLE 3 | Recurrent de novo mutations of SCN8A in epileptic
encephalopathy.
Amino acid
substitution
Nucleotide
substitution
Exon Channel
domain
CpG # Reference
p.Asn215Asp c.643 A>G 6A DIS3 No 2 DECIPHER 2015 (25)
p.Ala890Thr c.2668 G>A 16 DIIS5 No 2 (25, 53)
p.Ile1327Val c.3979 A>G 22 DIIIS4-5 No 2 (19, 27)
p.Arg1617Gln c.4850 G>A 27 DIVS4 Yes 5 (16, 21, 23, 25, 53)
p.Ala1650Thr c.4948 G>A 27 DIVS4-5 No 2 (23, 25)
p.Arg1872Trp c.5614 C>T 27 C-term Yes 9 (17, 23, 25),
unpublished obs.p.Arg1872Gln c.5615G>A
p.Arg1872Leu c.5615 G>T
for interacting proteins, including sodium channel beta subunit
β1 (31), intracellular FGFs (32–34), and calmodulin (35). The
final 1/3 of the C-terminus, downstream of the calmodulin-
binding motif, is disordered and not well-conserved. Most of the
mutated residues in EIEE13 are located in the highly conserved
portions of the protein: the domains containing transmembrane
segments, inactivation gate, and proximal 2/3 of the C-terminus
of Nav1.6 (Figure 3). In contrast, the non-pathogenic variants
reported in the ExAC database of more than 60,000 exomes
[Exome Aggregation Consortium, Cambridge, MA, USA
(URL: http://exac.broadinstitute.org), accessed 04/2015] are
concentrated in the non-conserved cytoplasmic loops of the
channel (Figure 3).
Five mutations of SCN8A have been tested in functional assays
in transfected cells (Table 4). Three of these have dramatic gain-
of-function effects. p.Asn1768Asp causes impaired channel inac-
tivation and elevated persistent sodium current (15). As predicted
by these experiments, transfection of primary hippocampal neu-
rons with the mutant Nav1.6 cDNA increases neuronal excitabil-
ity and promotes spontaneous firing (15). Similar missense
mutations causing increased persistent current have also been
identified in three other neuronal sodium channels. SCN1Amuta-
tions with increased persistent current were observed in patients
with generalized epilepsy with febrile seizures plus (GEFS+) and
FIGURE 2 |Mechanism for recurrent mutation of SCN8A at CpG
dinucleotides. Arginine 1617 is encoded by a CGA codon, and arginine
1872 is encoded by a CGG codon. Both contain CpG dinucleotides on
coding and non-coding strands (small arrows). Cytosine methylation followed
by deamination on either strand leads to mutation: at arginine 1617,
replacement by the premature termination codon (TGA, Ter) or glutamine
(Gln); at arginine 1872, replacement by tryptophan (Trp) or glutamine (Gln).
The premature termination mutation p.Arg1617Ter has not been seen in
EIEE13 patients, and would probably not cause seizures (see text).
Dravet Syndrome (36–38). SCN2A mutations with delayed inac-
tivation and increased persistent current were described in both
human and mouse (39–43). An SCN3A mutation with increased
persistent current was identified in a child with pediatric partial
epilepsy (44, 45). Thus, increased persistent current is a com-
mon pathological mechanism in epilepsy due to sodium channel
mutations.
Two additional SCN8A mutations, p.Thr767Ile and p.Asn
984Lys, cause a hyperpolarized shift in the voltage-dependence
of activation, which is predicted to result in premature neuronal
firing (22, 24). Hyperpolarized shifts in activation have also been
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FIGURE 3 | Differential distribution of pathogenic and non-pathogenic
variants in the protein domains of SCN8A. Mutations of patients with
EIEE13 are compared with variation in the ExAC database
(exac.broadinstitute.org, accessed 04/2015), which excludes severe
pediatric disease. Each amino acid substitution was counted once. Data
were available for 43 mutations in EIEE13 patients and 228 variants from the
ExAC database. Filled bars, EIEE13 patients; open bars, ExAC controls;
Inact. gate, inactivation gate.
TABLE 4 | Functional effects of five SCN8A mutations in patients with
epileptic encephalopathy.
Amino acid
substitution
Channel
domain
Cell
assay
Effect on function Reference
p.Arg223Gly DIS4 HEK Partial LOF, protein
unstable at 37°C
(20)
p.Thr767Ile DIIS1 ND7/23 GOF, hyperpolarizing
shift in activation voltage
(22)
p.Asn984Lys Near
DIIS6
HEK GOF, hyperpolarizing
shift in activation voltage
(24)
p.Gly1451Ser DIIIS6 HEK LOF, no activity at 37°C (24)
p.Asn1768Asp DIVS6 ND7/23 GOF, increased
persistent current
(15)
observed in missense mutations of SCN1A and SCN2A that cause
early-onset epilepsy (46–48). Elevated activity of Nav1.6 thus
appears to be the cause of seizures in these two cases.
The two mutations of SCN8A with apparent loss-of-function
in transfected cell assays are puzzling. Simple loss-of-function
mutations caused by protein truncation do not cause seizures in
human ormouse (3, 13). It seemsmost likely that these two patient
mutations actually exhibit gain-of-function in vivo. p.Gly1451Ser
encodes a stable protein that lacks channel activity in transfected
cells (24). p.Arg223Gly, results in protein instability at 37°C,
greatly reducing current density but at 30°C, partial function
is restored (20). At 30°C, activation and inactivation kinetics
do not differ from wildtype but the mutant channel generates
elevated ramp current in response to slow ramp depolarizations
(20). Increased ramp current is a gain-of-function property that
has been observed in a mutation of Nav1.3 in pediatric partial
epilepsy (44, 45). Because the p.Arg223Gly mutation affects the
second arginine residue in the DIS4 voltage sensor, it may also
cause increased gating pore current, as observed for pathogenic
mutations of Nav1.4 in periodic paralysis and Nav1.5 in dilated
cardiomyopathy (49, 50). Thus, these two apparently inactive
channel proteins may exhibit gain-of-function features in vivo.
Thorough analysis of additional patientmutationswill be required
for definition of the relationship between genotype and phenotype
of missense substitutions in SCN8A.
Modeling SCN8A Epileptic Encephalopathy
in the Mouse
The earliest models of Scn8a dysfunction in themouse had partial
or complete loss of channel activity, and did not exhibit seizures
(3). To generate a mouse model of EIEE13, we introduced the
patient mutation p.Asn1768Asp into the mouse genome (51).
Heterozygous Scn8aN1768D/+ mice recapitulate several features of
EIEE13, including spontaneous convulsive seizures, ataxia, and
sudden death (52). In heterozygous mutant mice, seizure onset
occurs at 2–4months of age. The mice may have several gener-
alized tonic–clonic seizures per day, and progress to sudden death
within 1month of seizure onset.
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Like many patients, the heterozygous Scn8aN1768D/+ mice have
normal EEG prior to seizure onset (52). After seizure onset,
they exhibit sporadic, semiperiodic biphasic slow wave or sharp
wave–slow wave complexes. In addition, there are multiple daily
interictal epileptiform discharges with diffuse polyspikes or single
spike–wave discharges, similar to those in EIEE13. These dis-
charges are frequently accompanied bymyoclonic jerks or spasms.
Unlike the patients, the mice do not demonstrate impaired learn-
ing or behavior, brain atrophy, or structural abnormalities of the
brain. This novel Scn8a mouse model will be useful for investi-
gation of pathogenesis and mechanisms of SUDEP. It will also be
useful for evaluation of new therapies.
Conclusion
Large-scale sequencing of patient exomes has revealed the role
of SCN8A in human epilepsy. Mutation of SCN8A accounts
for approximately 1% of EIEE. The predominance of de novo
mutations in children with EIEE13 reflects the severity of the
disorder, which prevents transmission to the next generation.
One-third of the mutations in EIEE13 are recurrent, and most
occur in highly conserved regions of the channel. Further
analysis of the functional effects of additional SCN8A muta-
tions will be required to generate a comprehensive view of
structure/function relationships. Functional differences among
pathogenic mutations of SCN8A will have implications for selec-
tion of treatment for individual patients and for development of
new therapies.
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